209 related articles for article (PubMed ID: 16330573)
1. Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma.
Essman SC; Lewis MR; Miller WH
J Nucl Med; 2005 Dec; 46(12):2076-82. PubMed ID: 16330573
[TBL] [Abstract][Full Text] [Related]
2. Effects of 153Sm-ethylenediaminetetramethylene phosphonate on physeal and articular cartilage in juvenile rabbits.
Essman SC; Lattimer J; Cook JL; Turnquist S; Kuroki K
J Nucl Med; 2003 Sep; 44(9):1510-5. PubMed ID: 12960200
[TBL] [Abstract][Full Text] [Related]
3. Effects of increasing doses of samarium-153-ethylenediaminetetramethylene phosphonate on axial and appendicular skeletal growth in juvenile rabbits.
Essman SC; Lewis MR; Fox DB
Nucl Med Biol; 2008 Feb; 35(2):219-25. PubMed ID: 18312832
[TBL] [Abstract][Full Text] [Related]
4. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
Bayouth JE; Macey DJ; Kasi LP; Fossella FV
J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
[TBL] [Abstract][Full Text] [Related]
6. ESR dosimetry of 89Sr and 153Sm in bone.
Kinoshita A; Braga FJ; Graeff CF; Baffa O
Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
[TBL] [Abstract][Full Text] [Related]
7. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].
Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY
Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908
[TBL] [Abstract][Full Text] [Related]
8. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
9. Estimated human absorbed dose of a new (153)Sm bone seeking agent based on biodistribution data in mice: Comparison with (153)Sm-EDTMP.
Yousefnia H; Zolghadri S
Phys Med; 2015 Nov; 31(7):714-9. PubMed ID: 26095757
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.
Loeb DM; Garrett-Mayer E; Hobbs RF; Prideaux AR; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
Cancer; 2009 Jun; 115(11):2514-22. PubMed ID: 19338063
[TBL] [Abstract][Full Text] [Related]
11. Samarium 153Sm lexidronam.
Lamb HM; Faulds D
Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
[TBL] [Abstract][Full Text] [Related]
12. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic and genotoxic effect of the [166Dy]Dy/166Ho-EDTMP in vivo generator system in mice.
Pedraza-López M; Ferro-Flores G; Arteaga de Murphy C; Morales-Ramírez P; Piedras-Ross J; Murphy-Stack E; Hernández-Oviedo O
Nucl Med Biol; 2004 Nov; 31(8):1079-85. PubMed ID: 15607490
[TBL] [Abstract][Full Text] [Related]
14. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
15. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.
Loeb DM; Hobbs RF; Okoli A; Chen AR; Cho S; Srinivasan S; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
Cancer; 2010 Dec; 116(23):5470-8. PubMed ID: 20715156
[TBL] [Abstract][Full Text] [Related]
16. Radiation absorbed dose calculations for samarium-153-EDTMP localized in bone.
Heggie JC
J Nucl Med; 1991 May; 32(5):840-4. PubMed ID: 2022993
[TBL] [Abstract][Full Text] [Related]
17. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
[TBL] [Abstract][Full Text] [Related]
18. (170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.
Das T; Chakraborty S; Sarma HD; Tandon P; Banerjee S; Venkatesh M; Pillai MR
Nucl Med Biol; 2009 Jul; 36(5):561-8. PubMed ID: 19520297
[TBL] [Abstract][Full Text] [Related]
19. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
20. Internal dosimetry studies of
Shirmardi SP; Saniei E; Das T; Noorvand M; Erfani M; Bagheri R
Appl Radiat Isot; 2020 Dec; 166():109396. PubMed ID: 32889376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
